The metabolic memory phenomenon in predicting a risk for vascular complications in diabetes mellitus


如何引用文章

全文:

详细

The paper presents data on positive and negative metabolic memory phenomena in patients with type 1 and type 2 diabetes mellitus (DM) as exemplified by the long-term randomized trials DCCT, UKPDS, ACCORD, VADT, and ADVANCE. It discusses the role of metabolic memory in predicting a risk for vascular complications in DM. Ideas on the mechanisms of this phenomenon, which are based on the activation of oxidative stress, the production of irreversible glycation products, and epigenetic disorders, are given.

作者简介

I Dedov

M Shestakova

参考

  1. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968-983.
  2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
  3. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36:808-812.
  4. Тhe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329:683-689.
  5. Nathan David M. for the DCCT/EDIC Research group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care. 2014;37:9-16.
  6. Hirose A, Furushima D, Yamaguchi N, Kitano S, Uchigata Y. Prediction of retinopathy at 20 years after onset in younger-onset type 1 diabetes using mean metabolic memory-free HbA1c values. Diabetes Care. 2013;36(11):3812-3814.
  7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359:1577-1589.
  8. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358:2545-2559.
  9. Duckworth W, Abraira C, Moritz T et al. for the VADT Investigators. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360:129-139.
  10. Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, Applegate WB, Puntakee Z, Yale JF, Cushman WC; ACCORD Study Group. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87(3):649-159.
  11. Fioretto P., Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2):69-75.
  12. Hayward RA, Reaven PD, Wiitala WL et al. Follow-up of glycemic and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197-2206.
  13. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358:2560-2572.
  14. Zoungas S, Chalmers J, Neal B, ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406.
  15. Ceriello A, Ihnat MA, Thorpe JE. The «metabolic memory»: is more than just tight glucose control nessesary to prevent diabetic complications? J Clin Metab. 2009;94:410-415.
  16. Титов В.Н., Ширяева Ю.Н. Глюкоза, гликотоксины и продукты гликирования. Участие в патогенезе микроангиопатий, артериолосклероза и атеросклероза. Клиническая лабораторная диагностика. 2011;11:3-13.
  17. Cencioni C, Spallotta F, Greco S, Martelli F, Zeiher AM., Gaetano C. Epigenetic mechanisms of hyperglycemic memory. Int J Biochem Cell Biol. 2014;51:155-158.
  18. Corgnali M, Piconi L, Ihnat M, Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic «memory» induced by high glucose in isolated human endothelial cells. Diabetes Metab Res Rev. 2008;24:301-309.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2015

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##